浙江奥翔药业股份有限公司2025年半年度报告摘要

Core Viewpoint - The company, Zhejiang Ausun Pharmaceutical Co., Ltd., is preparing for its 2025 semi-annual performance briefing to provide investors with insights into its operational results and financial status for the first half of 2025 [6][7][10]. Company Overview - The company is identified by the stock code 603229 and is referred to as Ausun Pharmaceutical [5]. - The company has confirmed that all board members attended the board meeting [2]. Financial Data - The semi-annual report is unaudited [3]. - The company has not proposed any profit distribution or capital reserve conversion plans for the reporting period [4]. Important Matters - The company has indicated that there are no significant changes in its operational situation during the reporting period, nor any events that would have a major impact on its operations [4]. Investor Communication - The performance briefing is scheduled for September 9, 2025, from 15:00 to 16:00, and will be held at the Shanghai Stock Exchange Roadshow Center [6][8]. - Investors can submit questions for the briefing from September 2 to September 8, 2025, through the Roadshow Center's website or via email [6][9]. Fundraising and Usage - The company has conducted non-public stock offerings in 2020 and 2022, raising approximately RMB 420 million and RMB 485 million respectively, with net proceeds after expenses being RMB 408 million and RMB 474 million [11][12]. - As of June 30, 2025, the company has two fundraising special accounts for the 2020 offering and five for the 2022 offering [14][15]. - The company has utilized RMB 8 million of idle fundraising temporarily to supplement working capital, with RMB 6 million still outstanding as of June 30, 2025 [18][19]. - The company has not engaged in cash management or investment of idle funds during the reporting period [20]. Board and Supervisory Meetings - The fourth board meeting was held on August 28, 2025, where the semi-annual report and fundraising usage report were approved unanimously [36][39]. - The supervisory board also convened on the same day and approved the same reports, confirming their compliance with relevant laws and regulations [45][49].